The ALTTO study has now shown that patients with diabetes on metformin (but not insulin) at the time of their diagnosis of ER+ breast cancer have improved survival over similar patients with ER+ cancers who are not on metformin (this is true even for ER+ Her2+).
Sonnenblick A, Agbor-Tarh D, Bradbury I, et al. Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor-2 positive primary breast cancer: analysis from the ALTTO phase II randomized trial [published online May 2017]. J Clin Oncol. doi:10.1200/JCO.2016.69.7722
Blood test screening for #breastcancer and all cancers is the future and the future is coming quickly